β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now?

References

• Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007;120(1):10–27. doi:10.1016/j.ijcard.2007.01.069
   PubMed Web of Science ®Google Scholar
• Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance. Indian J Pharmacol. 2011;43(5):492–501. doi:10.4103/0253-7613.84947
   PubMed Web of Science ®Google Scholar
• Bond RA, Lucero Garcia-Rojas EY, Hegde A, Walker JKL. Therapeutic potential of targeting ß-arrestin. Front Pharmacol. 2019;10:124. doi:10.3389/fphar.2019.00124
   PubMed Web of Science ®Google Scholar
• Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26(21):2259–2268. doi:10.1093/eurheartj/ehi386
   PubMed Web of Science ®Google Scholar
• Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol. 2005;144(3):317–322. doi:10.1038/sj.bjp.0706048
   PubMed Web of Science ®Google Scholar
• Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26(3):615–629. doi:10.1185/03007990903533681
   PubMed Web of Science ®Google Scholar
• Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79(5):733–743. doi:10.1111/bcp.12543
   PubMed Web of Science ®Google Scholar
• Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol. 2013;168(4):3572–3579. doi:10.1016/j.ijcard.2013.05.068
   PubMed Web of Science ®Google Scholar
• Shen L, Shah BR, Reyes EM, et al. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347(dec09 7):f6745. doi:10.1136/bmj.f6745
   PubMedGoogle Scholar
• Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J. 1985;109(5):1192–1196. doi:10.1016/0002-8703(85)90707-0
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Bisoprolol fumarate. Available from: https://bnf.nice.org.uk/drug/bisoprolol-fumarate.html#sideEffects. Accessed October, 2020.
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2017.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Andell P, Erlinge D, Smith JG, et al. β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish Nationwide Observational Study. J Am Heart Assoc. 2015;4(4):e001611. doi:10.1161/JAHA.114.001611
   PubMed Web of Science ®Google Scholar
• Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105(Suppl 1):S44–9. doi:10.1016/S0954-6111(11)70010-5
   PubMedGoogle Scholar
• Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515–523. doi:10.2147/COPD.S79942
   PubMed Web of Science ®Google Scholar
• Farzam K. Beta blockers. Stat pearls [Internet]. Available from: https://www.statpearls.com/ArticleLibrary/viewarticle/18241. Accessed March, 2021.
   Google Scholar
• Rozec B, Erfanian M, Laurent K, Trochu J-N, Gauthier C. Nebivolol, a vasodilating selective β1-blocker, is a β3-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol. 2009;53(17):1532–1538. doi:10.1016/j.jacc.2008.11.057
   PubMed Web of Science ®Google Scholar
• Poirier L, Tobe SW. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5 Suppl):S9–S15. doi:10.1016/j.cjca.2013.12.001
   PubMed Web of Science ®Google Scholar
• Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535–540.
   PubMedGoogle Scholar
• Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:3041–3046. doi:10.2147/COPD.S144333
   PubMed Web of Science ®Google Scholar
• Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012;11(1):14. doi:10.1186/1475-2840-11-14
   PubMedGoogle Scholar
• Zhang X, Shen C, Zhai S, Liu Y, Yue WW, Han L. A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure. Exp Ther Med. 2016;12(4):2489–2496. doi:10.3892/etm.2016.3657
   PubMed Web of Science ®Google Scholar
• CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90(4):1765–1773. doi:10.1161/01.CIR.90.4.1765
   PubMed Web of Science ®Google Scholar
• CIBIS Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. doi:10.1016/S0140-6736(98)11181-9
   PubMed Web of Science ®Google Scholar
• Willenheimer R, van Veldhuisen D, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426–2435. doi:10.1161/CIRCULATIONAHA.105.582320
   PubMed Web of Science ®Google Scholar
• MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. doi:10.1016/S0140-6736(99)04440-2
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi:10.1093/eurheartj/ehi115
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the betablocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–1667. doi:10.1056/NEJM200105313442202
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–1355. doi:10.1056/NEJM199605233342101
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658. doi:10.1056/NEJM200105313442201
   PubMed Web of Science ®Google Scholar
• Bonet S, Agustí A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160(5):621–627. doi:10.1001/archinte.160.5.621
   PubMedGoogle Scholar
• Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346(jan16 1):f55. doi:10.1136/bmj.f55
   PubMedGoogle Scholar
• Kotecha D, Manzano L, Krum H, et al.Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855.
   PubMedGoogle Scholar
• Hoes AW. β blockers for heart failure. BMJ. 2016;353:i2074. doi:10.1136/bmj.i2074
   PubMedGoogle Scholar
• Lam PH, Gupta N, Dooley DJ, et al. Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate. Am J Med. 2018;131(12):1473–1481. doi:10.1016/j.amjmed.2018.07.008
   PubMed Web of Science ®Google Scholar
• Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2018;104(5):407–415. doi:10.1136/heartjnl-2017-311652
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26–35. doi:10.1093/eurheartj/ehx564
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Kajio H. Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction. Sci Rep. 2018;8(1):9556. doi:10.1038/s41598-018-27799-y
   PubMedGoogle Scholar
• Persson H, Rythe’n-Alder E, Melcher A, Erhardt L. Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. Br Heart J. 1995;74(2):140–148. doi:10.1136/hrt.74.2.140
   PubMedGoogle Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136(6):e137–e161. doi:10.1161/CIR.0000000000000509
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730–1737. doi:10.1136/bmj.318.7200.1730
   PubMed Web of Science ®Google Scholar
• Andreasen C, Andersson C. Current use of beta-blockers in patients with coronary artery disease. Trends Cardiovasc Med. 2018;28(6):382–389. doi:10.1016/j.tcm.2017.12.014
   PubMed Web of Science ®Google Scholar
• Peyracchia M, Errigo D, Raposeiras Rubin S, et al. Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results. J Cardiovasc Med (Hagerstown). 2018;19(7):337–343. doi:10.2459/JCM.0000000000000662
   PubMed Web of Science ®Google Scholar
• Andersson C, Shilane D, Go AS, et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64(3):247–252. doi:10.1016/j.jacc.2014.04.042
   PubMed Web of Science ®Google Scholar
• Sorbets E, Steg PG, Young R, et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2018. doi:10.1093/eurheartj/ehy811
   Web of Science ®Google Scholar
• Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll Cardiol. 1996;28(1):20–24. doi:10.1016/0735-1097(96)00122-2
   PubMed Web of Science ®Google Scholar
• von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS investigators. J Am Coll Cardiol. 1995;25(1):231–238. doi:10.1016/0735-1097(94)00345-Q
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Bertrand M, Remme W, et al. The treatment effect of an ace-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovasc Drugs Ther. 2017;31(4):391–400. doi:10.1007/s10557-017-6747-9
   PubMed Web of Science ®Google Scholar
• Seo GW, Kim DK, Kim KH, et al. Impact of carvedilol versus β1-selective β blockers (bisoprolol, metoprolol, and nebivolol) in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2015;116(10):1502–1508. doi:10.1016/j.amjcard.2015.08.013
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. doi:10.1093/eurheartj/ehv320
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;127(4):e362–425. doi:10.1161/CIR.0b013e3182742c84
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;130(25):e344–426. doi:10.1161/CIR.0000000000000134
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164. doi:10.1016/j.jacc.2012.07.013
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477.
   PubMed Web of Science ®Google Scholar
• Isted A, Williams R, Oakeshott P. Secondary prevention following myocardial infarction: a clinical update. Br J Gen Pract. 2018;68(668):151–152. doi:10.3399/bjgp18X695261
   PubMed Web of Science ®Google Scholar
• Goldberger JJ, Bonow RO, Cuffe M, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66(13):1431–1441. doi:10.1016/j.jacc.2015.07.047
   PubMed Web of Science ®Google Scholar
• Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017;69(24):2885–2896. doi:10.1016/j.jacc.2017.04.001
   PubMed Web of Science ®Google Scholar
• Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71(2):201–230. doi:10.1016/j.jacc.2017.11.025
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003. doi:10.1002/14651858.CD002003.pub5
   PubMedGoogle Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545–1553. doi:10.1016/S0140-6736(05)67573-3
   PubMed Web of Science ®Google Scholar
• Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737–1742. doi:10.1503/cmaj.060110
   PubMed Web of Science ®Google Scholar
• Grossman E, Goldbourt U. Meta-analyses of antihypertensive therapy: are some of them misleading? Curr Hypertens Rep. 2001;3(5):381–386. doi:10.1007/s11906-001-0054-2
   PubMedGoogle Scholar
• Khan N, McAlister FA. Do beta-blockers have a role in treating hypertension? Yes. Can Fam Physician. 2007;53(4):614–621.
   PubMedGoogle Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(may19 1):b1665. doi:10.1136/bmj.b1665
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A, et al. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens. 2015;33(7):1321–1341. doi:10.1097/HJH.0000000000000614
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–1419.
   PubMed Web of Science ®Google Scholar
• Grassi G. Sympathetic overdrive in hypertension: clinical and therapeutic relevance. An article from the e-journal of the ESC council for cardiology practice. Eur Soc Cardiol. 2015;13:6–24.
   Google Scholar
• Santilli F, Simeone P, D’Ardes D, Davì G. The deadly line linking sympathetic overdrive, dipping status and vascular risk: critical appraisal and therapeutic implications. Hypertens Res. 2016;39(6):404–406. doi:10.1038/hr.2016.27
   PubMed Web of Science ®Google Scholar
• Trap-Jensen J, Carlsen JE, Svendsen TL, Christensen NJ. Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans. Eur J Clin Invest. 1979;9(3):181–183. doi:10.1111/j.1365-2362.1979.tb00920.x
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. Beta-blockers in the treatment of hypertension. BMJ. 2009;338.
   PubMedGoogle Scholar
• Bloom HL, Vinik AI, Colombo J. Differential effects of adrenergic antagonists (carvedilol vs metoprolol) on parasympathetic and sympathetic activity: a comparison of clinical results. Heart Int. 2014;9(1):15–21. doi:10.5301/HEART.2014.12496
   PubMedGoogle Scholar
• Ågesen FN, Weeke PE, Tfelt-Hansen P, Tfelt-Hansen J;. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol Res Perspect. 2019;7(4):e00496. doi:10.1002/prp2.496
   PubMed Web of Science ®Google Scholar
• Zulkifly H, Lip GYH, Lane DA, et al. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018;72(3):e13070. doi:10.1111/ijcp.13070
   PubMed Web of Science ®Google Scholar
• Adderley NJ, Ryan R, Nirantharakumar K, Marshall T. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart. 2019;105(1):27–33. doi:10.1136/heartjnl-2018-312977
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–844. doi:10.1001/jama.1994.03510350050036
   PubMed Web of Science ®Google Scholar
• Banach M, Rysz J, Drozdz JA, et al. Risk factors of atrial fibrillation following coronary artery bypass grafting: a preliminary report. Circ J. 2006;70(4):438–441. doi:10.1253/circj.70.438
   PubMed Web of Science ®Google Scholar
• Megens MR, Churilov L, Thijs V, et al. New-onset atrial fibrillation after coronary artery bypass graft and long-term risk of stroke: a meta-analysis. J Am Heart Assoc. 2017;6(12):e007558. doi:10.1161/JAHA.117.007558
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRs focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2019;74(1):104–132. doi:10.1016/j.jacc.2019.01.011
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• National Institute for health and Care Excellence. Atrial fibrillation: management. Clinical guideline [CG180]; June 2014. Available from: https://www.nice.org.uk/guidance/cg180/chapter/1-Recommendations#rate-and-rhythm-control. Accessed October, 2020.
   Google Scholar